177478-46-5

Upstream product

• 177478-45-4 (2E)-3-[6-(acetylamino)-3-pyridinyl]-N-{2-[2,4-dichloro-3-(hydroxymethyl)methylanilino]-2-oxoethyl}-2-propenamide 
• 177477-90-6 3-(N-Glycyl-N-methylamino)-1-(tert-butyldiphenyl-silyloxymethyl)-2,6-dichlorobenzene 
• 160648-18-0 (E)-3-(6-acetylamino-pyridin-3-yl)acrylic acid 
• 177478-44-3 3-[N-[(E)-3-(6-Acetamidopyridin-3-yl)acryloylglycyl)-N-methylamino]-1-[tert-butyldiphenylsilyloxymethyl]-2,6-dichlorobenzene 

Relevant academic research and scientific papers

A New Class of Nonpeptide Bradykinin B2 Receptor Ligand, Incorporating a 4-Aminoquinoline Framework. Identification of a Key Pharmacophore to Determine Species Difference and Agonist/Antagonist Profile

Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B2 receptor antagonists afforded highly potent ligands for human B2 receptor with various affinities for guine

Benzimidazole compounds as bradykinin antagonists

PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk